Caris Life Sciences® (Caris), a leading AI TechBio company, today unveiled the enhanced Caris Assure®, a new evolution of liquid biopsy. By integrating Whole Exome Sequencing (WES), Whole ...

The high complexity and diversity of the eukaryotic transcriptome poses significant challenges for the efficient detection of specific transcripts. Conventional targeted RNA-seq methods often require ...

The global transcriptome sequencing market is projected to reach $11.8 billion by 2035, growing at a 7.3% CAGR from 2025 to 2035. Growth is driven by falling sequencing costs, precision medicine, drug ...

The enhanced version of Caris Assure includes validation that tumor fraction correlates with risk of progression and treatment efficacy in patients who receive repeated testing, and results are ...

An overview of where next-generation sequencing is used, from whole-genome variant discovery to clinical liquid biopsy and single-cell transcriptomics.

Genetic variants that cause rare disorders may remain elusive even after expansive testing, such as exome sequencing. The diagnostic yield of genome sequencing, particularly after a negative ...

Low-dose radiation as a preconditioning regimen for dendritic cell vaccines. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not include a full text component.

This image illustrates the typical steps in next-generation sequencing (excluding single-molecule sequencing methods). The process begins with isolating genomic DNA (a) and breaking it into short ...

This eBook explores advances in RNA sequencing (RNA-seq), with key content from BioTechniques’ digital hub and Taylor & Francis journals, Biotechnology and Genetic Engineering Reviews, Immunological ...

Caris Life Sciences introduces the next evolution of liquid biopsy with enhanced Caris Assure: Irving, Texas Wednesday, September 30, 2026, 12:00 Hrs [IST] Caris Life Sciences, In ...